Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 975 - 983 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5398 İndeks Tarihi: 14-12-2022

Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading

Öz:
Background/aim: The nucleolus has the potential to provide insight into how many types of cancer will progress. In this study, we examined the evaluation of the nucleolus with a microscope in widespread breast cancer tumors and whether this value contributes to tumor grading as an objective clinicopathological parameter. Materials and methods: In our study, the nucleolus was evaluated retrospectively in resections with a diagnosis of invasive breast carcinoma of the cases between January 2010 and April 2021. In total, the tumor nucleolus of 377 cases of invasive breast carcinoma was evaluated. Nucleolus evaluation was performed with light microscopy using four different modes (modified Helpap method, in 1, 5, and 10 high power fields at 40x magnification). The relationship between nucleolar scores and clinicopathological parameters was examined separately. Regrading was performed by replacing nuclear pleomorphism with the nucleolar score in the classically used histological grading system and utilizing the nucleolus score as the fourth parameter in this grading system. Results: There was no significant correlation between the prognosis of the patients and the nucleolar score. When nuclear pleomor- phism and nucleolar score were replaced in the classical grading system, disease-free and overall survival were correlated with the new grading system. In addition, a relationship was found between high nucleolus score and other clinicopathological parameters (such as estrogen receptor negativity, progesterone receptor negativity, high Ki-67, triple negative, and human epidermal growth factor recep- tor-2 status). Conclusion: The presence of nucleolus is associated with disease-free survival and overall survival of patients, and it can be evaluated with a light microscope at no extra cost and time. Therefore, in the classical grading, using it instead of nuclear pleomorphism with low reproducibility among pathologists may provide more objective results in predicting patient prognosis.
Anahtar Kelime: Breast cancers nucleolus prominence light microscopy

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. Progress in Molecular Biology and Translational Science 2017; 151: 1-32. doi: 10.1016/bs.pmbts.2017.07.002
  • 2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19 (5): 403-410. doi: 10.1111/j.1365- 2559.1991.tb00229.x
  • 3. Rakha EA, Ahmed MA, Aleskandarany MA, Hodi Z, Lee AH et al. Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology 2017; 70 (4): 632-642. doi: 10.1111/his.13117
  • 4. Huang J, Bay BH, Tan PH. Nuclear morphology in breast cancer: is pleomorphism an illusion? Medical Hypotheses 2000; 55 (1): 26-28. doi: 10.1054/mehy.1999.0980
  • 5. Elsharawy KA, Toss MS, Raafat S, Ball G, Green AR et al. Prognostic significance of nucleolar assessment in invasive breast cancer. Histopathology 2020; 76 (5): 671-684. doi: 10.1111/his.14036
  • 6. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nature Reviews. Cancer 2004; 4 (9): 677-687. doi: 10.1038/ nrc1430
  • 7. Pianese G. Beitraege zur Histologie und Aetiologie der Carconoms.[Contributions to the histology and etiology of carcinomas]. Beitr Pathol Anat Allgem Pathology 1896; 142: 1-193.
  • 8. Derenzini M, Montanaro L, Treré D. What the nucleolus says to a tumour pathologist. Histopathology 2009; 54 (6): 753-762. doi: 10.1111/j.1365-2559.2008.03168.x
  • 9. Maccarty, William Carpenter. The value of the macronucleolus in the cancer problem. The American Journal of Cancer 1936; 26 (3): 529-532.
  • 10. Lam YW, Trinkle-Mulcahy L, Lamond AI. The nucleolus. Journal of cell science 2005; 118 (7): 1335-1337. doi: 10.1242/ jcs.01736
  • 11. Montanaro L, Treré D, Derenzini M. Nucleolus, ribosomes, and cancer. The American Journal of Pathology 2008; 173 (2): 301- 310. doi: 0.2353/ajpath.2008.070752
  • 12. Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012; 22 (1): 51-65. doi: 10.1016/j.ccr.2012.05.019
  • 13. Fischer AH, Bardarov S Jr, Jiang Z. Molecular aspects of diagnostic nucleolar and nuclear envelope changes in prostate cancer. Journal of Cellular Biochemistry 2004; 91 (1): 170-184. doi: 10.1002/jcb.10735
  • 14. Hernandez-Verdun D. The nucleolus: a model for the organization of nuclear functions. Histochemical Cell Biology 2006; 126 (2): 135-148. doi: 10.1007/s00418-006-0212-3
  • 15. Zhong S, Zhang C, Johnson DL. Epidermal growth factor enhances cellular TATA binding protein levels and induces RNA polymerase I- and III-dependent gene activity. Molecular and Cellular Biology 2004; 24 (12): 5119-5129. doi: 10.1128/ MCB.24.12.5119-5129.2004
  • 16. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nature Cell Biology 2005; 7 (3): 311-318. doi: 10.1038/ncb1224
  • 17. Derenzini M, Treré D, O’Donohue MF, & Ploton, D. Interphase nucleolar organiser regions in tumour pathology. Molecular Biology in Cellular Pathology 2003: 137.
  • 18. Lorenzato M, Abboud P, Lechki C, Browarnyj F, O’Donohue MF et al. Proliferation assessment in breast cancer: a double- staining technique for AgNOR quantification in MIB-1 positive cells especially adapted for image cytometry. Micron 2000; 31 (2): 151-159. doi: 10.1016/s0968-4328(99)00072-4
  • 19. Rakha EA, Allison KH, Ellis IO, Horii R, Masuda S et al. Invasive breast carcinoma: General overview. Breast tumours WHO classification of tumours. 5th Ed. Lyon: World Health Organization, 5 ed. Lyon IARC; 2019. p. 82-101
  • 20. Helpap B, Knüpffer J, Essmann S. Nucleolar grading of renal cancer. Correlation of frequency and localization of nucleoli to histologic and cytologic grading and stage of renal cell carcinomas. Modern Pathology 1990; 3 (6): 671-678.
  • 21. Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Seminars in Cancer Biology 2020; 60: 14-27. doi: 10.1016/j.semcancer.2019.08.012
  • 22. Helpap B. Grading and prognostic significance of urologic carcinomas. Urologia Internationalis 1992; 48 (3): 245-257. doi: 10.1159/000282345
  • 23. Montanaro L, Treré D, Derenzini M. Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential. Biochimica et biophysica acta 2012; 1825 (1): 101-110. doi: 10.1016/j.bbcan.2011.10.006
  • 24. Bacalini MG, Pacilli A, Giuliani C, Penzo M, Treré D et al.The nucleolar size is associated to the methylation status of ribosomal DNA in breast carcinomas. BMC Cancer 2014; 22 (14): 361. doi: 10.1186/1471-2407-14-361
  • 25. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch. 1999; 434 (1): 3-10. doi: 10.1007/s004280050297
  • 26. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Modern Pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 2005; 18 (8):1067-1078. doi: 10.1038/modpathol.3800388
  • 27. Rakha EA, Bennett RL, Coleman D, Pinder SE, Ellis IO et al. Reviewofthenationalexternalqualityassessment(EQA)scheme for breast pathology in the UK. Journal of Clinical Pathology 2017; 70 (1): 51-57. doi: 10.1136/jclinpath-2016-203800
  • 28. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. American Journal of Clinical Pathology 1995; 103 (2): 195-198. doi: 10.1093/ ajcp/103.2.195
APA DUMAN ÖZTÜRK S, Öztürk Ç, okcu o, Şen B, Bedir R (2022). Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. , 975 - 983. 10.55730/1300-0144.5398
Chicago DUMAN ÖZTÜRK Seda,Öztürk Çiğdem,okcu oguzhan,Şen Bayram,Bedir Recep Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. (2022): 975 - 983. 10.55730/1300-0144.5398
MLA DUMAN ÖZTÜRK Seda,Öztürk Çiğdem,okcu oguzhan,Şen Bayram,Bedir Recep Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. , 2022, ss.975 - 983. 10.55730/1300-0144.5398
AMA DUMAN ÖZTÜRK S,Öztürk Ç,okcu o,Şen B,Bedir R Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. . 2022; 975 - 983. 10.55730/1300-0144.5398
Vancouver DUMAN ÖZTÜRK S,Öztürk Ç,okcu o,Şen B,Bedir R Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. . 2022; 975 - 983. 10.55730/1300-0144.5398
IEEE DUMAN ÖZTÜRK S,Öztürk Ç,okcu o,Şen B,Bedir R "Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading." , ss.975 - 983, 2022. 10.55730/1300-0144.5398
ISNAD DUMAN ÖZTÜRK, Seda vd. "Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading". (2022), 975-983. https://doi.org/10.55730/1300-0144.5398
APA DUMAN ÖZTÜRK S, Öztürk Ç, okcu o, Şen B, Bedir R (2022). Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. Turkish Journal of Medical Sciences, 52(4), 975 - 983. 10.55730/1300-0144.5398
Chicago DUMAN ÖZTÜRK Seda,Öztürk Çiğdem,okcu oguzhan,Şen Bayram,Bedir Recep Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. Turkish Journal of Medical Sciences 52, no.4 (2022): 975 - 983. 10.55730/1300-0144.5398
MLA DUMAN ÖZTÜRK Seda,Öztürk Çiğdem,okcu oguzhan,Şen Bayram,Bedir Recep Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.975 - 983. 10.55730/1300-0144.5398
AMA DUMAN ÖZTÜRK S,Öztürk Ç,okcu o,Şen B,Bedir R Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. Turkish Journal of Medical Sciences. 2022; 52(4): 975 - 983. 10.55730/1300-0144.5398
Vancouver DUMAN ÖZTÜRK S,Öztürk Ç,okcu o,Şen B,Bedir R Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading. Turkish Journal of Medical Sciences. 2022; 52(4): 975 - 983. 10.55730/1300-0144.5398
IEEE DUMAN ÖZTÜRK S,Öztürk Ç,okcu o,Şen B,Bedir R "Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading." Turkish Journal of Medical Sciences, 52, ss.975 - 983, 2022. 10.55730/1300-0144.5398
ISNAD DUMAN ÖZTÜRK, Seda vd. "Nucleolus assessment in invasive breast carcinoma, an objective parameter for histological grading". Turkish Journal of Medical Sciences 52/4 (2022), 975-983. https://doi.org/10.55730/1300-0144.5398